Intellipharmaceutics International (NASDAQ: IPCI; TSX: I) is engaged in the research, development, and commercialization of controlled-release and targeted-release pharmaceutical products. Controlled-release means releasing a drug into the bloodstream or at a target site in the body, over an extended period of time or at predetermined times. In some circumstances, controlled-release drug delivery can enhance efficacy and patient compliance as compared to immediate-release formats for the same drug.
The Company has released a corporate presentation, current as of February 2012. Below is the presentation overview:
- Specialty Pharmaceuticals Company (NASDAQ: IPCI; TSX: I)
- Six ANDAs under review by the FDA for generics of: Focalin XR®, Effexor XR®, Protonix®, Glucophage® XR , Seroquel XR®, Lamictal® XR™ (represents approximately $6.6B of branded and generic sales)
- Rexista™ Technology – abuse resistant drug delivery platform
- Rexista Oxycodone XR - Phase I proof-of-concept study complete
- Potential application to other opioid drug candidates
- Controlled-Release (CR) Focus: high-value products / alt. delivery systems
- $15B+ of CR medicines off patent in the near term (1)
- Technical barriers can result in fewer competitors and higher margins
- Strategic alliance with Par Pharmaceutical (NYSE: PRX) for generic Focalin XR
- Broad range of drug delivery solutions
- 30+ patents issued and pending
The presentation also includes information on the following:
- The management team
- Profile of the pharmaceutical industry
- Hypermatrix technology
- Disclosed product candidates
- IPCI's 6 ANDAs (abbreviated new drug application)
- Rexista technology platform
- Oxycodone and its abuse
- Growing interest in abuse resistance
- Rexista Oxycodone XR
- IPCI's state-of-the-art facility
- Company milestones
- Selected financial data